SCHEMBL376288

SCHEMBL376288

CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)Nc4ccc(I)cc4)cc3OC)nc2N1C1CCCC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 17/20 0.79
PLK3 Q9H4B4 14/20 0.79
PLK2 Q9NYY3 13/20 0.79
PRKD3 O94806 3/20 0.78
CLK2 P49760 3/20 0.78
PTK2 Q05397 3/20 0.78
CAMK2G Q13555 3/20 0.78
CAMK2D Q13557 3/20 0.78
PRKD2 Q9BZL6 3/20 0.78
CSNK1G1 Q9HCP0 3/20 0.78
CSNK1G3 Q9Y6M4 3/20 0.78
MAP4K4 O95819 2/20 0.78
PRKCG P05129 2/20 0.78
RPS6KA3 P51812 2/20 0.78
NEK4 P51957 2/20 0.78
SRPK1 Q96SB4 1/20 0.78
BRD4 O60885 6/20 0.74
ALK Q9UM73 4/20 0.74
BRDT Q58F21 2/20 0.74
DAPK3 O43293 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376563 0.90 PLK1 (0.74) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL22930147 0.89 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL25785977 0.89 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL25768793 0.89 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL376050 0.88 PLK1 (0.71) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL24851804 0.88 PLK1 (1.00) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL16971992 0.87 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL12825254 0.87 PLK1 (0.84) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL29922386 0.87 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL29453442 0.87 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079743-B1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD (GB) 2012-01-25 EP disclosed
EP-2079743-B1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD (GB) 2012-01-25 EP disclosed
US-20100216802-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. (GB) 2010-08-26 US disclosed
US-20100216802-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. (GB) 2010-08-26 US disclosed
US-20100216802-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. (GB) 2010-08-26 US disclosed
WO-2008050096-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. (GB) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216802-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER PLK2, PLK4, PLK3 PLK1 7/4885PLK3 3/4885PLK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.